查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1862445

动物mRNA疫苗：全球市场份额和排名、总收入和需求预测（2025-2031年）

mRNA Vaccines for Animals - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 109 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球动物 mRNA 疫苗市场规模预计为 8,102 万美元，预计到 2031 年将达到 25.13 亿美元，在预测期（2025-2031 年）内以 61.1% 的复合年增长率增长。

动物mRNA疫苗是一种兽用疫苗，它利用传讯RNA（mRNA）技术刺激牲畜、宠物和其他动物产生针对特定病原体的免疫反应。这类疫苗透过将编码病毒或细菌抗原的合成mRNA导入动物细胞，诱导免疫系统辨识并对抗目标病原体。与传统疫苗相比，mRNA疫苗具有研发週期更短、疗效更高以及能够快速适应新出现的动物疾病等优势。目前，mRNA疫苗正被探索用于多种用途，包括牲畜疾病（例如口蹄疫）、通用感染疾病以及伴侣动物健康管理。

市场机会与关键驱动因素

作为新一代生物製药，动物mRNA疫苗凭藉其快速研发、高特异性和扩充性，正在重塑全球兽用疫苗格局。根据动物保健相关企业的年度报告和证券公司的调查，畜牧业对疾病预防的需求持续增长，尤其针对跨境感染疾病和重大动物传染病，加速了对新型疫苗的投资。 mRNA技术在人类新冠疫苗中的成功应用，为其在兽用领域的应用潜力提供了有力支撑。此外，在食品安全、畜牧业现代化和公共卫生等领域的强有力政策支持下，动物mRNA疫苗的市场潜力巨大。

市场挑战、风险与限制因素

儘管前景广阔，动物mRNA疫苗仍面临许多挑战。其储存、运输和大规模生产需要严格的低温运输和先进的设施，因此成本高于传统疫苗。法规结构尚不完善，註册和安全检验标准的地区差异也为商业化带来了不确定性。此外，该行业由拥有技术和资金优势的大型跨国动物保健公司主导，这为面临激烈竞争和潜在技术障碍的小型公司设定了准入门槛。

下游需求趋势

随着畜牧业生产规模扩大、密集程度提高，以及消费者对食品安全和动物健康的意识增强，对安全有效的新型疫苗的需求持续成长。家禽、生猪和伴侣动物领域对新发疾病的快速反应疫苗的需求尤其强劲。政府加大对动物疾病预防的投入，以及养殖户减少损失、提高效率的需求，都将进一步推动疫苗的普及应用。长远来看，动物mRNA疫苗可望成为保障畜牧业生产稳定和食品供应安全的关键技术。

本报告旨在按地区/国家、类型和应用对全球兽用mRNA疫苗市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以销售收入为指标，对动物mRNA疫苗市场规模、估算和预测进行了呈现，以2024年为基准年，并涵盖了2020年至2031年的历史数据和预测数据。报告运用定量和定性分析相结合的方法，帮助读者制定业务/成长策略，评估市场竞争格局，分析自身在当前市场中的地位，并就动物mRNA疫苗做出明智的商业决策。

市场区隔

公司

  • Ceva Animal Health
  • Merck Animal Health
  • Areterna
  • Bayer
  • BioNTech
  • Genvax Technologies
  • BioVenic
  • Moderna
  • Ruipu Biotechnology
  • Jinyu Bio-technology
  • Shanghai Shen Lian Biomedical
  • Suzhou Kerui Meide Biomedical Technology
  • Shanghai Rnacure Biopharma

按类型分類的细分市场

  • 非复製型mRNA疫苗
  • 自复製mRNA疫苗

应用领域

  • 猪
  • 家禽
  • 伴侣动物
  • 反刍动物

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for mRNA Vaccines for Animals was estimated to be worth US$ 81.02 million in 2024 and is forecast to a readjusted size of US$ 2513 million by 2031 with a CAGR of 61.1% during the forecast period 2025-2031.

mRNA vaccines for animals are a type of veterinary vaccine that use messenger RNA (mRNA) technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into the animal's cells, prompting the immune system to recognize and fight the targeted disease. Compared to traditional vaccines, mRNA vaccines offer faster development timelines, improved efficacy, and the ability to rapidly adapt to emerging animal diseases. They are being explored for various applications, including livestock diseases (such as foot-and-mouth disease), zoonotic infections, and companion animal health.

Market Development Opportunities & Main Driving Factors

mRNA vaccines for animals, as a new generation of biological products, are reshaping the global veterinary vaccine landscape with their rapid development, high specificity, and scalability. According to annual reports from animal health companies and brokerage research, the demand for epidemic prevention in the livestock industry continues to rise, particularly against transboundary infectious diseases and major animal epidemics, which accelerates investment in novel vaccines. The proven success of mRNA technology in human COVID-19 vaccines validates its potential in veterinary applications. Coupled with strong policy support for food safety, livestock modernization, and public health, the market expansion potential for animal mRNA vaccines is significant.

Market Challenges, Risks, & Restraints

Despite promising prospects, animal mRNA vaccines face multiple challenges. Their storage, transportation, and mass production require stringent cold chain and advanced equipment, leading to higher costs compared to traditional vaccines. Regulatory frameworks remain immature, with varying standards for registration and safety validation across regions, adding uncertainty to commercialization. Additionally, the industry is dominated by multinational animal health giants with strong technological and financial advantages, creating barriers for smaller firms facing fierce competition and potential technological hurdles.

Downstream Demand Trends

As livestock farming becomes increasingly large-scale and intensive, and as consumer awareness of food safety and animal health grows, demand for safe and effective novel vaccines continues to rise. In particular, poultry, swine, and companion animal sectors exhibit strong demand for rapid-response vaccines against emerging diseases. Growing government investment in animal disease prevention and farmers' need to reduce losses and improve efficiency will further drive adoption. In the long term, animal mRNA vaccines are poised to become a critical technology supporting livestock stability and food supply security.

This report aims to provide a comprehensive presentation of the global market for mRNA Vaccines for Animals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of mRNA Vaccines for Animals by region & country, by Type, and by Application.

The mRNA Vaccines for Animals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Vaccines for Animals.

Market Segmentation

By Company

  • Ceva Animal Health
  • Merck Animal Health
  • Areterna
  • Bayer
  • BioNTech
  • Genvax Technologies
  • BioVenic
  • Moderna
  • Ruipu Biotechnology
  • Jinyu Bio-technology
  • Shanghai Shen Lian Biomedical
  • Suzhou Kerui Meide Biomedical Technology
  • Shanghai Rnacure Biopharma

Segment by Type

  • Non-replicating mRNA vaccines
  • Self-replicating mRNA vaccines

Segment by Application

  • Pigs
  • Poultry
  • Companion Animals
  • Ruminants

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of mRNA Vaccines for Animals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of mRNA Vaccines for Animals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of mRNA Vaccines for Animals in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 mRNA Vaccines for Animals Product Introduction
  • 1.2 Global mRNA Vaccines for Animals Market Size Forecast (2020-2031)
  • 1.3 mRNA Vaccines for Animals Market Trends & Drivers
    • 1.3.1 mRNA Vaccines for Animals Industry Trends
    • 1.3.2 mRNA Vaccines for Animals Market Drivers & Opportunity
    • 1.3.3 mRNA Vaccines for Animals Market Challenges
    • 1.3.4 mRNA Vaccines for Animals Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global mRNA Vaccines for Animals Players Revenue Ranking (2024)
  • 2.2 Global mRNA Vaccines for Animals Revenue by Company (2020-2025)
  • 2.3 Key Companies mRNA Vaccines for Animals Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies mRNA Vaccines for Animals Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of mRNA Vaccines for Animals
  • 2.6 mRNA Vaccines for Animals Market Competitive Analysis
    • 2.6.1 mRNA Vaccines for Animals Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by mRNA Vaccines for Animals Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Animals as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Non-replicating mRNA vaccines
    • 3.1.2 Self-replicating mRNA vaccines
  • 3.2 Global mRNA Vaccines for Animals Sales Value by Type
    • 3.2.1 Global mRNA Vaccines for Animals Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global mRNA Vaccines for Animals Sales Value, by Type (2020-2031)
    • 3.2.3 Global mRNA Vaccines for Animals Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Pigs
    • 4.1.2 Poultry
    • 4.1.3 Companion Animals
    • 4.1.4 Ruminants
  • 4.2 Global mRNA Vaccines for Animals Sales Value by Application
    • 4.2.1 Global mRNA Vaccines for Animals Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global mRNA Vaccines for Animals Sales Value, by Application (2020-2031)
    • 4.2.3 Global mRNA Vaccines for Animals Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global mRNA Vaccines for Animals Sales Value by Region
    • 5.1.1 Global mRNA Vaccines for Animals Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global mRNA Vaccines for Animals Sales Value by Region (2020-2025)
    • 5.1.3 Global mRNA Vaccines for Animals Sales Value by Region (2026-2031)
    • 5.1.4 Global mRNA Vaccines for Animals Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America mRNA Vaccines for Animals Sales Value, 2020-2031
    • 5.2.2 North America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
    • 5.3.2 Europe mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific mRNA Vaccines for Animals Sales Value, 2020-2031
    • 5.4.2 Asia Pacific mRNA Vaccines for Animals Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America mRNA Vaccines for Animals Sales Value, 2020-2031
    • 5.5.2 South America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa mRNA Vaccines for Animals Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions mRNA Vaccines for Animals Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions mRNA Vaccines for Animals Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.3.2 United States mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.4.2 Europe mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.5.2 China mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.6.2 Japan mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.7.2 South Korea mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.8.2 Southeast Asia mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India mRNA Vaccines for Animals Sales Value, 2020-2031
    • 6.9.2 India mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Ceva Animal Health
    • 7.1.1 Ceva Animal Health Profile
    • 7.1.2 Ceva Animal Health Main Business
    • 7.1.3 Ceva Animal Health mRNA Vaccines for Animals Products, Services and Solutions
    • 7.1.4 Ceva Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Ceva Animal Health Recent Developments
  • 7.2 Merck Animal Health
    • 7.2.1 Merck Animal Health Profile
    • 7.2.2 Merck Animal Health Main Business
    • 7.2.3 Merck Animal Health mRNA Vaccines for Animals Products, Services and Solutions
    • 7.2.4 Merck Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Merck Animal Health Recent Developments
  • 7.3 Areterna
    • 7.3.1 Areterna Profile
    • 7.3.2 Areterna Main Business
    • 7.3.3 Areterna mRNA Vaccines for Animals Products, Services and Solutions
    • 7.3.4 Areterna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Areterna Recent Developments
  • 7.4 Bayer
    • 7.4.1 Bayer Profile
    • 7.4.2 Bayer Main Business
    • 7.4.3 Bayer mRNA Vaccines for Animals Products, Services and Solutions
    • 7.4.4 Bayer mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bayer Recent Developments
  • 7.5 BioNTech
    • 7.5.1 BioNTech Profile
    • 7.5.2 BioNTech Main Business
    • 7.5.3 BioNTech mRNA Vaccines for Animals Products, Services and Solutions
    • 7.5.4 BioNTech mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.5.5 BioNTech Recent Developments
  • 7.6 Genvax Technologies
    • 7.6.1 Genvax Technologies Profile
    • 7.6.2 Genvax Technologies Main Business
    • 7.6.3 Genvax Technologies mRNA Vaccines for Animals Products, Services and Solutions
    • 7.6.4 Genvax Technologies mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Genvax Technologies Recent Developments
  • 7.7 BioVenic
    • 7.7.1 BioVenic Profile
    • 7.7.2 BioVenic Main Business
    • 7.7.3 BioVenic mRNA Vaccines for Animals Products, Services and Solutions
    • 7.7.4 BioVenic mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.7.5 BioVenic Recent Developments
  • 7.8 Moderna
    • 7.8.1 Moderna Profile
    • 7.8.2 Moderna Main Business
    • 7.8.3 Moderna mRNA Vaccines for Animals Products, Services and Solutions
    • 7.8.4 Moderna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Moderna Recent Developments
  • 7.9 Ruipu Biotechnology
    • 7.9.1 Ruipu Biotechnology Profile
    • 7.9.2 Ruipu Biotechnology Main Business
    • 7.9.3 Ruipu Biotechnology mRNA Vaccines for Animals Products, Services and Solutions
    • 7.9.4 Ruipu Biotechnology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Ruipu Biotechnology Recent Developments
  • 7.10 Jinyu Bio-technology
    • 7.10.1 Jinyu Bio-technology Profile
    • 7.10.2 Jinyu Bio-technology Main Business
    • 7.10.3 Jinyu Bio-technology mRNA Vaccines for Animals Products, Services and Solutions
    • 7.10.4 Jinyu Bio-technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Jinyu Bio-technology Recent Developments
  • 7.11 Shanghai Shen Lian Biomedical
    • 7.11.1 Shanghai Shen Lian Biomedical Profile
    • 7.11.2 Shanghai Shen Lian Biomedical Main Business
    • 7.11.3 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Products, Services and Solutions
    • 7.11.4 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Shanghai Shen Lian Biomedical Recent Developments
  • 7.12 Suzhou Kerui Meide Biomedical Technology
    • 7.12.1 Suzhou Kerui Meide Biomedical Technology Profile
    • 7.12.2 Suzhou Kerui Meide Biomedical Technology Main Business
    • 7.12.3 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Products, Services and Solutions
    • 7.12.4 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Suzhou Kerui Meide Biomedical Technology Recent Developments
  • 7.13 Shanghai Rnacure Biopharma
    • 7.13.1 Shanghai Rnacure Biopharma Profile
    • 7.13.2 Shanghai Rnacure Biopharma Main Business
    • 7.13.3 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Products, Services and Solutions
    • 7.13.4 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Shanghai Rnacure Biopharma Recent Developments

8 Industry Chain Analysis

  • 8.1 mRNA Vaccines for Animals Industrial Chain
  • 8.2 mRNA Vaccines for Animals Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 mRNA Vaccines for Animals Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 mRNA Vaccines for Animals Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. mRNA Vaccines for Animals Market Trends
  • Table 2. mRNA Vaccines for Animals Market Drivers & Opportunity
  • Table 3. mRNA Vaccines for Animals Market Challenges
  • Table 4. mRNA Vaccines for Animals Market Restraints
  • Table 5. Global mRNA Vaccines for Animals Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global mRNA Vaccines for Animals Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies mRNA Vaccines for Animals Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies mRNA Vaccines for Animals Product Type
  • Table 9. Key Companies Time to Begin Mass Production of mRNA Vaccines for Animals
  • Table 10. Global mRNA Vaccines for Animals Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Animals as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global mRNA Vaccines for Animals Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global mRNA Vaccines for Animals Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global mRNA Vaccines for Animals Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global mRNA Vaccines for Animals Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global mRNA Vaccines for Animals Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global mRNA Vaccines for Animals Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global mRNA Vaccines for Animals Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global mRNA Vaccines for Animals Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global mRNA Vaccines for Animals Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global mRNA Vaccines for Animals Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global mRNA Vaccines for Animals Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global mRNA Vaccines for Animals Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global mRNA Vaccines for Animals Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global mRNA Vaccines for Animals Sales Value by Region (2020-2025) & (%)
  • Table 27. Global mRNA Vaccines for Animals Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions mRNA Vaccines for Animals Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions mRNA Vaccines for Animals Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions mRNA Vaccines for Animals Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Ceva Animal Health Basic Information List
  • Table 32. Ceva Animal Health Description and Business Overview
  • Table 33. Ceva Animal Health mRNA Vaccines for Animals Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Ceva Animal Health (2020-2025)
  • Table 35. Ceva Animal Health Recent Developments
  • Table 36. Merck Animal Health Basic Information List
  • Table 37. Merck Animal Health Description and Business Overview
  • Table 38. Merck Animal Health mRNA Vaccines for Animals Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Merck Animal Health (2020-2025)
  • Table 40. Merck Animal Health Recent Developments
  • Table 41. Areterna Basic Information List
  • Table 42. Areterna Description and Business Overview
  • Table 43. Areterna mRNA Vaccines for Animals Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Areterna (2020-2025)
  • Table 45. Areterna Recent Developments
  • Table 46. Bayer Basic Information List
  • Table 47. Bayer Description and Business Overview
  • Table 48. Bayer mRNA Vaccines for Animals Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Bayer (2020-2025)
  • Table 50. Bayer Recent Developments
  • Table 51. BioNTech Basic Information List
  • Table 52. BioNTech Description and Business Overview
  • Table 53. BioNTech mRNA Vaccines for Animals Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in mRNA Vaccines for Animals Business of BioNTech (2020-2025)
  • Table 55. BioNTech Recent Developments
  • Table 56. Genvax Technologies Basic Information List
  • Table 57. Genvax Technologies Description and Business Overview
  • Table 58. Genvax Technologies mRNA Vaccines for Animals Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Genvax Technologies (2020-2025)
  • Table 60. Genvax Technologies Recent Developments
  • Table 61. BioVenic Basic Information List
  • Table 62. BioVenic Description and Business Overview
  • Table 63. BioVenic mRNA Vaccines for Animals Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in mRNA Vaccines for Animals Business of BioVenic (2020-2025)
  • Table 65. BioVenic Recent Developments
  • Table 66. Moderna Basic Information List
  • Table 67. Moderna Description and Business Overview
  • Table 68. Moderna mRNA Vaccines for Animals Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Moderna (2020-2025)
  • Table 70. Moderna Recent Developments
  • Table 71. Ruipu Biotechnology Basic Information List
  • Table 72. Ruipu Biotechnology Description and Business Overview
  • Table 73. Ruipu Biotechnology mRNA Vaccines for Animals Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Ruipu Biotechnology (2020-2025)
  • Table 75. Ruipu Biotechnology Recent Developments
  • Table 76. Jinyu Bio-technology Basic Information List
  • Table 77. Jinyu Bio-technology Description and Business Overview
  • Table 78. Jinyu Bio-technology mRNA Vaccines for Animals Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Jinyu Bio-technology (2020-2025)
  • Table 80. Jinyu Bio-technology Recent Developments
  • Table 81. Shanghai Shen Lian Biomedical Basic Information List
  • Table 82. Shanghai Shen Lian Biomedical Description and Business Overview
  • Table 83. Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Shanghai Shen Lian Biomedical (2020-2025)
  • Table 85. Shanghai Shen Lian Biomedical Recent Developments
  • Table 86. Suzhou Kerui Meide Biomedical Technology Basic Information List
  • Table 87. Suzhou Kerui Meide Biomedical Technology Description and Business Overview
  • Table 88. Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Suzhou Kerui Meide Biomedical Technology (2020-2025)
  • Table 90. Suzhou Kerui Meide Biomedical Technology Recent Developments
  • Table 91. Shanghai Rnacure Biopharma Basic Information List
  • Table 92. Shanghai Rnacure Biopharma Description and Business Overview
  • Table 93. Shanghai Rnacure Biopharma mRNA Vaccines for Animals Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in mRNA Vaccines for Animals Business of Shanghai Rnacure Biopharma (2020-2025)
  • Table 95. Shanghai Rnacure Biopharma Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. mRNA Vaccines for Animals Downstream Customers
  • Table 99. mRNA Vaccines for Animals Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. mRNA Vaccines for Animals Product Picture
  • Figure 2. Global mRNA Vaccines for Animals Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global mRNA Vaccines for Animals Sales Value (2020-2031) & (US$ Million)
  • Figure 4. mRNA Vaccines for Animals Report Years Considered
  • Figure 5. Global mRNA Vaccines for Animals Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by mRNA Vaccines for Animals Revenue in 2024
  • Figure 7. mRNA Vaccines for Animals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Non-replicating mRNA vaccines Picture
  • Figure 9. Self-replicating mRNA vaccines Picture
  • Figure 10. Global mRNA Vaccines for Animals Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global mRNA Vaccines for Animals Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Pigs
  • Figure 13. Product Picture of Poultry
  • Figure 14. Product Picture of Companion Animals
  • Figure 15. Product Picture of Ruminants
  • Figure 16. Global mRNA Vaccines for Animals Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global mRNA Vaccines for Animals Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America mRNA Vaccines for Animals Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific mRNA Vaccines for Animals Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions mRNA Vaccines for Animals Sales Value (%), (2020-2031)
  • Figure 29. United States mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India mRNA Vaccines for Animals Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India mRNA Vaccines for Animals Sales Value by Application (%), 2024 VS 2031
  • Figure 50. mRNA Vaccines for Animals Industrial Chain
  • Figure 51. mRNA Vaccines for Animals Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed